Embla Medical (EMBLA) Q1 2025 earnings summary

Executive summary

• Q1 2025 sales reached $203 million, with 4% organic growth, driven by strong performance in Prosthetics & Neuro Orthotics, especially in EMEA (+7%) and APAC (+13%), while Americas saw a slight decline after a strong Q4 2024 due to lower Patient Care volumes.

• EBITDA margin improved to 18%, up 1 percentage point year-over-year, supported by cost reductions, product mix, and continued cost control.

• Net profit rose 45% to $12 million (6% of sales), compared to $8 million (4% of sales) in Q1 2024, reflecting stronger operations and absence of special items.

• Share buyback program was reinitiated in February 2025, with approximately 300,000 shares repurchased in Q1.

• New executive appointments: André Rocha as EVP R&D and Conal Harte as EVP Patient Care.

Financial highlights

• Gross profit margin expanded to 63% from 62% (before special items) in Q1 2024, driven by manufacturing efficiencies and favorable product mix.

• OPEX stable at 52% of sales; effective tax rate at 23% for Q1 2025.

• Free cash flow was $8 million (4% of sales), a turnaround from negative $7 million in Q1 2024, aided by lower CAPEX and strong operations.

• CAPEX was $6 million (3% of sales), expected to normalize at 3-4% of sales for the rest of the year.

• Cash generated by operations was $23 million (11% of sales), up from $13 million (7% of sales) a year earlier.

Outlook and guidance

• Full-year 2025 guidance reiterated: 5%-8% organic sales growth and 20%-21% EBITDA margin.

• Guidance assumes impact from U.S. trade tariffs, with mitigation expected through supply chain adjustments, though the effect remains uncertain.

• Patient volumes in the U.S. expected to pick up later in the year despite a slow Q1, with no change to annual expectations.

• APAC growth in Q1 was boosted by backlog recovery in Australia; less impact expected in H2.

• CAPEX expected at 3-4% of sales; effective tax rate guidance at 23-24%.